ID

33872

Descripción

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140); ODM derived from: https://clinicaltrials.gov/show/NCT02038946

Link

https://clinicaltrials.gov/show/NCT02038946

Palabras clave

Versiones (1)
  1. 4/1/19 4/1/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

4 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Lymphoma NCT02038946

Inglés

Eligibility Lymphoma NCT02038946

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT02038946
Criteria
Descripción

Criteria

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
grade 1, 2, or 3a fl without pathologic evidence of transformation
Descripción

Follicular Lymphoma Grade | Transformation Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0024301
UMLS CUI [1,2]
C0441800
UMLS CUI [2,1]
C1536010
UMLS CUI [2,2]
C0332197
male and female, ages 18 and above, with relapsed or refractory fl lymphoma after > or =2 prior treatment lines; each of the 2 prior treatment lines must include at least cd20 antibody and/or an alkylating agent
Descripción

Age | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Status post Therapeutic procedure Quantity | Therapeutic procedure Including CD20 Antibody | Therapeutic procedure Including Alkylating Agent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C1335701
UMLS CUI [3]
C1335723
UMLS CUI [4,1]
C0231290
UMLS CUI [4,2]
C0087111
UMLS CUI [4,3]
C1265611
UMLS CUI [5,1]
C0087111
UMLS CUI [5,2]
C0332257
UMLS CUI [5,3]
C3891557
UMLS CUI [6,1]
C0087111
UMLS CUI [6,2]
C0332257
UMLS CUI [6,3]
C0002073
eastern cooperative oncology group (ecog) performance status (ps) 0-1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
known central nervous system lymphoma
Descripción

Central nervous system lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0742472
history of interstitial lung disease
Descripción

Lung Disease, Interstitial

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0206062
subjects with active, known or suspected autoimmune disease
Descripción

Autoimmune Disease | Autoimmune Disease Suspected

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2,1]
C0004364
UMLS CUI [2,2]
C0750491
prior allogeneic stem cell transplant
Descripción

Allogeneic Stem Cell Transplantation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2242529
prior autologous stem cell transplant ≤12 weeks prior to first dose of study drug
Descripción

Transplantation of autologous hematopoietic stem cell

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1831743
Volver a la parte superior de la página

Similar models

Eligibility Lymphoma NCT02038946

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT02038946
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
Follicular Lymphoma Grade | Transformation Absent
Item
grade 1, 2, or 3a fl without pathologic evidence of transformation
boolean
C0024301 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
C1536010 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Age | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Status post Therapeutic procedure Quantity | Therapeutic procedure Including CD20 Antibody | Therapeutic procedure Including Alkylating Agent
Item
male and female, ages 18 and above, with relapsed or refractory fl lymphoma after > or =2 prior treatment lines; each of the 2 prior treatment lines must include at least cd20 antibody and/or an alkylating agent
boolean
C0001779 (UMLS CUI [1])
C1335701 (UMLS CUI [2])
C1335723 (UMLS CUI [3])
C0231290 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
C0087111 (UMLS CUI [5,1])
C0332257 (UMLS CUI [5,2])
C3891557 (UMLS CUI [5,3])
C0087111 (UMLS CUI [6,1])
C0332257 (UMLS CUI [6,2])
C0002073 (UMLS CUI [6,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status (ps) 0-1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Central nervous system lymphoma
Item
known central nervous system lymphoma
boolean
C0742472 (UMLS CUI [1])
Lung Disease, Interstitial
Item
history of interstitial lung disease
boolean
C0206062 (UMLS CUI [1])
Autoimmune Disease | Autoimmune Disease Suspected
Item
subjects with active, known or suspected autoimmune disease
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Allogeneic Stem Cell Transplantation
Item
prior allogeneic stem cell transplant
boolean
C2242529 (UMLS CUI [1])
Transplantation of autologous hematopoietic stem cell
Item
prior autologous stem cell transplant ≤12 weeks prior to first dose of study drug
boolean
C1831743 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial